IgA deficiency allergic transfusion reaction and its prevention and treatment strategies
Journal Title: Chinese Journal of Blood Transfusion - Year 2024, Vol 37, Issue 6
Abstract
IgA deficiency allergic transfusion reaction often occurs in patients with anti-IgA. When blood products containing IgA are transfused into these patients, it may lead to severe allergic transfusion reactions, which can be fatal in severe cases. This review summarizes the clinical manifestations and influencing factors of immunoglobulin A deficiency (IgAD), as well as the pathogenesis, laboratory test and prevention strategies of allergic transfusion reactions caused by IgA deficiency, so as to enhance prevention awareness of IgA deficiency allergic transfusion reaction in medical staff.
Authors and Affiliations
Qiuhong MO, Xuejun LIU, Yi LIU, Xian LI
Keywords
Related Articles
- EP ID EP742792
- DOI 10.13303/j.cjbt.issn.1004-549x.2024.06.017
- Views 14
- Downloads 0
Influence of blood donation before pregnancy on neonatal birth weight
Objective To explore the influence of maternal blood donation before pregnancy on neonatal birth weight. Methods A total of 6 428 full-term (gestational age ≥37 weeks) singleton pregnant women in Ningbo Medical Center Li...
Cases report and diagnosis and treatment of passenger lymphocyte syndrome after liver and renal transplantation
Objective To summarize the clinical features, serological features, blood transfusion protocols and treatment of 3 cases of passenger lymphocyte syndrome(PLS) after ABO-incompatibility liver and renal transplantation in...
Efficacy and safety of platelet-rich plasma for acute achilles tendon injury: a meta-analysis
Objective To evaluate the clinical efficacy and safety of platelet-rich plasma(PRP) in acute achilles tendon injury by meta-analysis. Methods Literature on clinical randomized controlled trial of PRP in the treatment of...
Evaluation of the efficacy and safety of human coagulation factor Ⅷ in the treatment of hemophilia A patients
Objective To evaluate the efficacy and safety of human coagulation factor Ⅷ developed by Shenzhen Weiguang Biological products Co, Ltd in the treatment of patients with hemophilia A. Methods A prospective, multi-center,...
Analysis on phenotype and genotyping of CisAB subtypes: 12 Cases
Objective To analyze and master the serological and genetic characteristics of the samples with CisAB subtype and their genetic background. Methods From January 2018 to January 2022, blood samples with discrepant ABO blo...